Novaliq GmbH Announces Launch Of A Phase 1 Study Following US And European Patent Approval Of Cyclasol® (Cyclosporin) Eye Drops
4/3/2014 9:15:57 AM
HEIDELBERG, Germany--(BUSINESS WIRE)--Novaliq GmbH today announced the commencement of a Phase 1 study for CyclASol (Cyclosporin solution) following US and European patent approval of the solution for the treatment of dry eye syndrome.
Help employers find you! Check out all the jobs and post your resume.
comments powered by